Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Breast 1

Conditions

Prostatic Neoplasms 6Ovarian Neoplasms 4Neoplasms 3Endometrial Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Colorectal Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1Biliary Tract Neoplasms 1Advanced Breast Cancer 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Neoplasms × AZD5305 × Clear all
NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06713369 2026-03-04

AZD5305

AstraZeneca

Phase 1 Recruiting
8 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT05573724 2024-06-18

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡